Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 4, 2014

View Archived Issues

Atreca and Janssen Biotech collaborate in autoimmune diseases

Nuvilex to develop treatments that combine Cell-in-a-Box and cannabinoid-based medicine

First patient dosed in phase Ia trial of SYN-004 for the prevention of C. difficile infection

Evotec and Sanofi propose major strategic alliance to accelerate drug discovery

Imugene updates preclinical findings for HER-Vaxx

Novel CDK4/6 inhibitor is active in models of rheumatoid arthritis

Compugen reports results for drug target candidate identified through new methodology

Launch of Glanatek Ophthalmic Solution, a new treatment for glaucoma and ocular hypertension

Phase I results reported for glioma vaccine SurVaxM

Peloton Therapeutics conducts phase I trial of PT-2385 in advanced ccRCC

Astellas to end license agreement with Janssen for ASP-015K

Discovery of a novel MAb able to inhibit sporozoite invasion of hepatocytes in vivo

Epirus Biopharmaceuticals launches infliximab biosimilar in India

Aeterna Zentaris and Sinopharm A-Think sign Chinese license agreement for zoptarelin doxorubicin

Johns Hopkins University patents novel proteasome inhibitors

Italy researchers prepare new FXR modulators

Janssen R&D Ireland discloses novel anti-HBV compounds

First-in-human results presented for the DVD-Ig ABT-122

New CPT-1 inhibitors designed at the University of Aberdeen

Merck Patent reports new DNA-PK inhibitors

Update on FDA orphan drug status designations

Shandong International Biotechnology Park and MRC Technology to co-develop Alzheimer's disease drug

Inhibition of GBP1:PIM1 interaction, a potential target to overcome paclitaxel resistance

Targovax to develop melanoma vaccine using prize funds

Sprint Bioscience's Vps34 inhibitors reduce tumor growth in breast cancer model

FDA approves Blincyto to treat relapsed or refractory B-cell precursor ALL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...